Amy E. McKee

3.9k citations
38 papers · 2.3k · h-index 25

Impact in

  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Lung Cancer Research Studies
  • Cancer Research top 5%
    • Cancer Genomics and Diagnostics

Papers in

Co-authors
Richard Pazdur (26 shared papers)Kirsten B. Goldberg (13 shared papers)Gideon M. Blumenthal (8 shared papers)Carol J. Thiele (4 shared papers)Patricia Keegan (10 shared papers)Zhijie Li (1 shared paper)Kun He (5 shared papers)Sriram Subramaniam (5 shared papers)
Journals
The Oncologist (14 papers)Clinical Cancer Research (8 papers)Journal of Clinical Oncology (3 papers)Experimental Biology and Medicine (1 paper)Frontiers in Oncology (1 paper)
Partner nations
United StatesFranceCanada

In The Last Decade

Amy E. McKee

38 papers receiving 2.3k citations

Peers

Amy E. McKee
Comparison fields: 5 of 98
  • Oncology 1.1k
  • Cancer Research 285
  • Immunology 331
  • Pulmonary and Respiratory Medicine 464
  • Neurology 181
Replace Vincenzo Damiano with:
Vincenzo Damiano Italy
In‐Gu Do South Korea
David F. Schaeffer Canada
Ben Markman Australia
Fabiana Tatangelo Italy
Ritu Roy United States
Yoichi Naito Japan
Thomas Bachelot France
Morten Mau‐Sørensen Denmark
Allan Topham United States
Amy E. McKee relative to Vincenzo Damiano Italy Vincenzo Damiano's profile →
Citations per field
00.5×2×4×5.4×
Vincenzo Damiano · 1×
Citations per year

Countries citing papers authored by Amy E. McKee

Since Specialization
Citations

This map shows the geographic impact of Amy E. McKee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy E. McKee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy E. McKee more than expected).

Fields of papers citing papers by Amy E. McKee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy E. McKee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy E. McKee. The network helps show where Amy E. McKee may publish in the future.

Co-authors

The 25 scholars most cited alongside Amy E. McKee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amy E. McKee Line = papers co-authored together Amy E. McKee links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#Work
1
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
The Oncologist ·Lee H. Pai-Scherf, Gideon M. Blumenthal, Hongshan Li, Sriram Subramaniam, Pallavi S. Mishra‐Kalyani, Kun He, Hong Zhao, Jingyu Yu, Mark Paciga, Kirsten B. Goldberg, Amy E. McKee, Patricia Keegan, Richard Pazdur
2017235
2
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Clinical Cancer Research ·Najat Bouchkouj, Yvette L. Kasamon, R. Angelo de Claro, Bindu George, Xue Lin, Shiowjen Lee, Gideon M. Blumenthal, Wilson W. Bryan, Amy E. McKee, Richard Pazdur
2018196
3
OnTrk—The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology
Clinical Cancer Research ·Carol J. Thiele, Zhijie Li, Amy E. McKee
2009193
4
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
The Oncologist ·Erin Larkins, Gideon M. Blumenthal, Weishi Yuan, Kun He, Rajeshwari Sridhara, Sriram Subramaniam, Hong Zhao, Chao Liu, Jingyu Yu, Kirsten B. Goldberg, Amy E. McKee, Patricia Keegan, Richard Pazdur
2017178
5
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations
The Oncologist ·Lauretta Odogwu, Luckson Mathieu, Gideon M. Blumenthal, Erin Larkins, Kirsten B. Goldberg, Norma Sue Griffin, Karen E. Bijwaard, Eunice Lee, Reena Philip, Xiaoping Jiang, Lisa Rodríguez, Amy E. McKee, Patricia Keegan, Richard Pazdur
2018174
6
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1
The Oncologist ·Lola A. Fashoyin‐Aje, Martha Donoghue, Huanyu Chen, Kun He, Janaki Veeraraghavan, Kirsten B. Goldberg, Patricia Keegan, Amy E. McKee, Richard Pazdur
2018174
7
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
The Oncologist ·Daniel L. Suzman, Sundeep Agrawal, Yang‐Min Ning, V. Ellen Maher, Laura L. Fernandes, Stella Karuri, Shenghui Tang, Rajeshwari Sridhara, Jason Schroeder, Kirsten B. Goldberg, Amna Ibrahim, Amy E. McKee, Richard Pazdur, Julia A. Beaver
2018142
8
Neuroblastoma Cells Isolated from Bone Marrow Metastases Contain a Naturally Enriched Tumor-Initiating Cell
Cancer Research ·Loen M. Hansford, Amy E. McKee, Libo Zhang, Rani E. George, J. Ted Gerstle, Paul S. Thorner, Kristen M. Smith, A. Thomas Look, Herman Yeger, Freda D. Miller, Meredith S. Irwin, Carol J. Thiele, David R. Kaplan
2007134
9
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Clinical Cancer Research ·Amanda J. Walker, Suparna Wedam, Laleh Amiri‐Kordestani, Erik Bloomquist, Shengui Tang, Rajeshwari Sridhara, Wei Chen, Todd R. Palmby, Jeanne Fourie Zirkelbach, Wentao Fu, Qi Liu, Amy Tilley, Geoffrey Kim, Paul G. Kluetz, Amy E. McKee, Richard Pazdur
2016109
10
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non–Small Cell Lung Cancer Following Crizotinib
Clinical Cancer Research ·Erin Larkins, Gideon M. Blumenthal, Huanyu Chen, Kun He, Rajiv Agarwal, Gerlie Gieser, Olen Stephens, Eias Zahalka, Kimberly Ringgold, Whitney S. Helms, Stacy S. Shord, Jingyu Yu, Hong Zhao, Gina Davis, Amy E. McKee, Patricia Keegan, Richard Pazdur
201696
11
The Role of the U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology
The Oncologist ·Amy E. McKee, Ann T. Farrell, Richard Pazdur, Janet Woodcock
201063
12
Successes and Challenges of PARP Inhibitors in Cancer Therapy
Frontiers in Oncology ·Tiffany K. Ricks, Haw-Jyh Chiu, Gwynn Ison, Geoffrey Kim, Amy E. McKee, Paul G. Kluetz, Richard Pazdur
201560
13
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy
The Oncologist ·Vishal Bhatnagar, Nicole Gormley, Lola Luo, Yuan Li Shen, Rajeshwari Sridhara, Sriram Subramaniam, Guoxiang Shen, Lian Ma, Stacy S. Shord, Kirsten B. Goldberg, Ann T. Farrell, Amy E. McKee, Richard Pazdur
201758
14
FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation
The Oncologist ·Patricia O’Neal, Virginia E. Kwitkowski, Lola Luo, Yuan Li Shen, Sriram Subramaniam, Stacy S. Shord, Kirsten B. Goldberg, Amy E. McKee, Edvardas Kaminskas, Ann T. Farrell, Richard Pazdur
201856
15
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
The Oncologist ·Gideon M. Blumenthal, Paul G. Kluetz, Julie A. Schneider, Kirsten B. Goldberg, Amy E. McKee, Richard Pazdur
201750
16
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia
The Oncologist ·Dianne Pulte, Jonathon Vallejo, Donna Przepiorka, Lei Nie, Ann T. Farrell, Kirsten B. Goldberg, Amy E. McKee, Richard Pazdur
201847
17
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma
Clinical Cancer Research ·Julia A. Beaver, Marc R. Theoret, Sirisha L. Mushti, Kun He, Meredith Libeg, Kirsten B. Goldberg, Rajeshwari Sridhara, Amy E. McKee, Patricia Keegan, Richard Pazdur
201745
18
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
The Oncologist ·Yvette L. Kasamon, Chia‐Wen Ko, Sriram Subramaniam, Lian Ma, Yuching Yang, Lei Nie, Stacy S. Shord, Donna Przepiorka, Ann T. Farrell, Amy E. McKee, Richard Pazdur
201837
19
FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
The Oncologist ·Elizabeth Pulte, Andrew Dmytrijuk, Lei Nie, Kirsten B. Goldberg, Amy E. McKee, Ann T. Farrell, Richard Pazdur
201834
20
An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies
Clinical Cancer Research ·Julia A. Beaver, Abraham Tzou, Gideon M. Blumenthal, Amy E. McKee, Geoffrey Kim, Richard Pazdur, Reena Philip
201633

About Amy E. McKee

Amy E. McKee is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Molecular Biology, having authored 38 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (7 papers), Lung Cancer Treatments and Mutations (6 papers), Statistical Methods in Clinical Trials (5 papers), Neuroblastoma Research and Treatments (4 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Biosimilars and Bioanalytical Methods (4 papers) and Biomedical Ethics and Regulation (4 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (285 citations), Immunology (331 citations), Pulmonary and Respiratory Medicine (464 citations) and Neurology (181 citations). Amy E. McKee has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Richard Pazdur, Kirsten B. Goldberg, Gideon M. Blumenthal, Carol J. Thiele, Patricia Keegan, Zhijie Li, Kun He, Sriram Subramaniam, Rajeshwari Sridhara and Ann T. Farrell. Their work appears in journals such as The Oncologist, Clinical Cancer Research, Journal of Clinical Oncology, Experimental Biology and Medicine and Frontiers in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vincenzo DamianoBreakdown of academic impact, for papers by In‐Gu DoBreakdown of academic impact, for papers by David F. SchaefferBreakdown of academic impact, for papers by Ben MarkmanBreakdown of academic impact, for papers by Fabiana TatangeloBreakdown of academic impact, for papers by Ritu RoyBreakdown of academic impact, for papers by Yoichi NaitoBreakdown of academic impact, for papers by Thomas BachelotBreakdown of academic impact, for papers by Morten Mau‐SørensenBreakdown of academic impact, for papers by Allan Topham